175 related articles for article (PubMed ID: 29550842)
1. Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases.
Baba K; Kaida H; Hattori C; Muraki K; Kugiyama T; Fujita H; Ishibashi M
Hell J Nucl Med; 2018; 21(1):15-23. PubMed ID: 29550842
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
[TBL] [Abstract][Full Text] [Related]
3. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
4. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
5. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G
Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis L; Goranitis I; Pirrie S; Pope A; Barton D; Collins S; Daunton A; McLaren D; O'Sullivan JM; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown JE; Chakraborti P; Hussain SA; Russell JM; Billingham LJ; James ND
BJU Int; 2017 Apr; 119(4):522-529. PubMed ID: 27256016
[TBL] [Abstract][Full Text] [Related]
7. Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study.
Ripamonti C; Fagnoni E; Campa T; Giardina V; Brunelli C; Pigni A; De Conno F
Support Care Cancer; 2007 Oct; 15(10):1177-84. PubMed ID: 17333295
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
Ouyang W; Liu JH; Liu WY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):390-1. PubMed ID: 17426002
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Wang Y; Tao H; Yu X; Wang Z; Wang M
Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
[TBL] [Abstract][Full Text] [Related]
10. Strontium-89 chloride in the treatment of bone metastases from breast cancer.
Baziotis N; Yakoumakis E; Zissimopoulos A; Geronicola-Trapali X; Malamitsi J; Proukakis C
Oncology; 1998; 55(5):377-81. PubMed ID: 9732212
[TBL] [Abstract][Full Text] [Related]
11. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience.
Lee CK; Aeppli DM; Unger J; Boudreau RJ; Levitt SH
Am J Clin Oncol; 1996 Apr; 19(2):102-7. PubMed ID: 8610630
[TBL] [Abstract][Full Text] [Related]
12. Strontium-89 therapy and imaging with bremsstrahlung in bone metastases.
Uchiyama M; Narita H; Makino M; Sekine H; Mori Y; Fukumitsu N; Kawakami K
Clin Nucl Med; 1997 Sep; 22(9):605-9. PubMed ID: 9298293
[TBL] [Abstract][Full Text] [Related]
13. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement.
Kraeber-Bodéré F; Campion L; Rousseau C; Bourdin S; Chatal JF; Resche I
Eur J Nucl Med; 2000 Oct; 27(10):1487-93. PubMed ID: 11083537
[TBL] [Abstract][Full Text] [Related]
14. [Strontium chloride (89Sr-chloride) fractional injection method for bone metastases treatment].
Fomin DK; Smirnov IuN; Tararukhina OB; Nazarov AA
Vopr Onkol; 2012; 58(1):116-8. PubMed ID: 22629840
[TBL] [Abstract][Full Text] [Related]
15. [89Sr Therapy for pain relief in patients with bone metastases].
Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
[TBL] [Abstract][Full Text] [Related]
16. [A strontium-89 injection: a simple treatment of painful bone metastases in patients with prostate cancer unresponsive to hormonal treatment].
Jager PL; Mensink HJ; van den Bergh AC; Piers DA
Ned Tijdschr Geneeskd; 1999 May; 143(19):969-73. PubMed ID: 10368715
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study.
Atahan L; Yildiz F; Cengiz M; Kaplan B; Ozkan M; Yazici G; Gündoğ M; Haydaroğlu A; Korcum AF; Sengöz M; Dinçer M; Akmansu M; Engin K; Hayran M
Support Care Cancer; 2010 Jun; 18(6):691-8. PubMed ID: 19484483
[TBL] [Abstract][Full Text] [Related]
18. Strontium chloride Sr 89 for treating pain from metastatic bone disease.
Nightengale B; Brune M; Blizzard SP; Ashley-Johnson M; Slan S
Am J Health Syst Pharm; 1995 Oct; 52(20):2189-95. PubMed ID: 8564588
[TBL] [Abstract][Full Text] [Related]
19. Strontium and samarium therapy for bone metastases from prostate carcinoma.
Dickie GJ; Macfarlane D
Australas Radiol; 1999 Nov; 43(4):476-9. PubMed ID: 10901963
[TBL] [Abstract][Full Text] [Related]
20. (89)Sr imaging with bremsstrahlung in patients with metastatic breast cancer.
Yoshimura M; Kohno N; Yamada K; Kaise H; Okamoto J; Uchida K; Hashimoto T; Koizumi K; Tokuuye K
Clin Nucl Med; 2012 Nov; 37(11):1035-40. PubMed ID: 23027203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
